While healthcare workers at a Boston healthcare system with severe allergies reported more reactions after receiving a COVID-19 mRNA vaccine, nearly all were able to safely complete the series, according to an observational study yesterday in JAMA Network Open.Researchers at Mass General Brigham and Harvard Medical School mined the electronic health records of 52,998 employees, of whom 97.6% received both doses of vaccine, and 0.9% reported a history of high-risk allergy.
The study period was Dec 14, 2020, to Feb 1, 2021. Participants completed a prevaccination allergy risk assessment and at least one postvaccination symptom survey during the 3 days after vaccination.Current contraindications to COVID-19 mRNA vaccination include a history